Cell therapies are powerful weapons for treating some cancers, but the manufacturing required is complex and time-consuming. Bristol Myers has previously had difficulties producing enough of its two CAR-T cancer therapies to keep up with demand.
Bristol Myers won approval of both the lymphoma treatment Breyanzi and the multiple myeloma therapy Abecma in early 2021. They are personalized treatments that require a multi-week process during which a patient’s immune cells are extracted, shipped to a production site, genetically engineered to attack cancer and then reinfused into the patient.
